Written by
in
Patients with type 2 diabetes (T2D) and comorbid obstructive sleep apnea (OSA) experience a 20% greater mortality benefit at 1 year when prescribed a GLP-1 receptor agonist compared to patients without OSA who are also prescribed the drug class.
